Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 14/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491042 | 0.98 | IKBKB (0.55) | IKBKBJAK2JAK3MEN1KMT2A | |
| Bicarbonate SCHEMBL5978745 | 0.92 | IKBKB (0.50) | IKBKBJAK2JAK3MEN1KMT2A | |
| Bicarbonate SCHEMBL5978736 | 0.92 | IKBKB (0.50) | IKBKBJAK2JAK3MEN1KMT2A | |
| Bicarbonate SCHEMBL5978731 | 0.90 | IKBKB (0.52) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL6611048 | 0.86 | PTK2 (0.55) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL5556399 | 0.86 | IKBKB (0.46) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL13930117 | 0.84 | IKBKB (0.42) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL5105544 | 0.84 | MEN1 (0.59) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL1563630 | 0.81 | CHEK1 (0.45) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL7055093 | 0.81 | IKBKB (0.43) | IKBKBJAK2JAK3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421079-B1 | THIOPHENYL COMPOUNDS AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| US-7098240-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-08-29 | — | — | US | disclosed |
| US-20040235821-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| EP-1421079-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010163-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235821-A1 | Novel compounds | ABCG2, UGT1A1, SULT1E1 | IKBKB 2823/4885JAK2 378/4885JAK3 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.